Recap: Plus Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Plus Therapeutics (NASDAQ:PSTV) reported Q4 earnings with a 35.0% beat on estimated EPS, reporting an EPS of $-0.7 versus an estimate of $-1.07. Revenue increased by $1.16 million from the same period last year. The company had previously beaten EPS estimates last quarter, which led to a 6.0% increase in share price the following day.
March 05, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics reported a significant beat on Q4 earnings and a notable increase in revenue compared to the same period last year.
The positive earnings report, especially the significant beat on EPS estimates and the increase in revenue, is likely to instill investor confidence and could lead to a short-term increase in stock price. Historical data shows a 6.0% increase in share price following the last quarter's earnings beat, suggesting a pattern that could repeat.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100